Adaptive Biotechnologies, Amgen use clonoSEQ as preferred MRD test

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Adaptive Biotechnologies Corp. entered into a global agreement with Amgen to use Adaptive’s next-generation sequencing-based clonoSEQ Assay to assess minimal residual disease across multiple drug development programs within the Amgen hematology portfolio.

Under the four-year agreement, Adaptive will receive annual development fees in addition to sequencing payments and regulatory milestones in exchange for providing MRD testing and analysis for ongoing and future clinical trials.

The partnership, which began in 2016 to assess MRD in acute lymphoblastic leukemia, demonstrates the increasing utility of MRD assessment in the clinic. Adaptive will leverage data generated under this partnership to continue building robust evidence that supports MRD as a validated measure of patient outcomes across multiple novel treatments and blood cancers.

Table of Contents

YOU MAY BE INTERESTED IN

The Trump administration did exactly what it said it would do to disorient anyone involved in making policy or touched by it. The president and his crew have “flooded the zone”—the term and the image are theirs, as is the strategy of dropping a flurry of executive orders and memoranda that shake the foundations of the American system of government, raising questions of legality and constitutionality, and, above all, making it a challenge for anyone to see the entire picture and think strategically.
In two raucous back-to-back hearings on Jan. 29 and Jan. 30, anti-vaccine crusader Robert F. Kennedy Jr. was grilled by members of the United States Senate Finance Committee and the Health, Education, Labor, and Pensions Committee as the Trump administration seeks his confirmation as secretary of the Department of Health and Human Services. 
Over the past century, groundbreaking cancer research in the U.S. has led to life-saving medical advances that benefit patients worldwide. Scientists often devote their lives to making discoveries, putting their scientific endeavors ahead of status, income, or lifestyle. Investigators work tirelessly, often seven days a week, to solve complex medical problems. These efforts often lead to game-changing outcomes that help us understand difficult medical challenges, advance technologies and develop new therapies. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login